Table 1 Clinical parameters of the study population

From: Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting

Continuous variable

Number of biopsy sessions

 

1 (n=79)

2 (n=146)

3 (n=84)

4 (n=64)

P

Total (n=373)

 

Mean

Median

Mean

Median

Mean

Median

Mean

Median

 

Mean

Median

Age at biopsy

62.7

63.9

63.0

62.5

64.1

64.0

66.4

66.5

0.011

63.8

64.2

Prebiopsy PSA

5.6

4.8

7.0

5.4

9.1

8.6

13.6

9.3

<0.001

8.3

6.3

Body mass index

28.5

28.0

29.0

27.8

28.3

27.8

28.6

28.1

0.767

28.7

27.9

No. of prior biopsy cores

13.7

12.0

25.3

20.0

37.9

30.5

<0.001

22.3

12.0

Categorical variables

Count (%)

Count (%)

Count (%)

Count (%)

P

Count (%)

Prebiopsy TURP

1 (1.3)

0 (0)

1 (1.2)

5 (7.8)

0.001

366 (98.1)

Prebiopsy diagnosis

      

 PIN

0 (0)

9 (6.2)

4 (4.8)

5 (7.8)

<0.001

18 (4.8)

 Elevated PSA

79 (100)

109 (74.7)

62 (73.8)

46 (71.9)

 

296 (79.4)

 ASAP

0 (0)

28 (19.2)

18 (21.4)

13 (20.3)

 

59 (15.8)

Tobacco

      

 Never

38 (48.1)

72 (49.2)

40 (47.6)

31 (48.4)

0.724

181 (48.5)

 Former

31 (39.2)

53 (36.3)

35 (41.7)

29 (45.3)

 

148 (39.7)

 Current

10 (12.7)

21 (14.4)

9 (10.7)

4 (6.3)

 

44 (11.8)

Hypertension

33 (41.8)

75 (50.3)

34 (40.5)

32 (50.0)

0.377

174 (46.3)

Diabetes

3 (3.8)

24 (16.4)

11 (13.1)

6 (9.4)

0.039

44 (11.8)

  1. Abbreviations: ASAP, atypical small acinar proliferation; PIN, prostatic intraepithelial neoplasia; PSA, prostate specific antigen; TURP, transurethral resection of the prostate.
  2. Bold indicates statistically significant.